The Novartis Institute for Tropical Diseases (NITD) is an independent research institute within NIBR that applies drug-discovery expertise to combat infectious tropical diseases. NITD is currently focused on parasitic pathogens, including malaria, cryptosporidiosis, and three major kinetoplastid diseases – human African trypanosomiasis (sleeping sickness), Chagas disease, and leishmaniasis. NITD scientists collaborate with academic and non-profit partners, including the Wellcome Trust, the Bill & Melinda Gates Foundation, Medicines for Malaria Venture, and the Swiss Tropical Public Health Institute. NITD and collaborators have discovered two novel classes of antimalarials, which are currently in phase II clinical trials.
Dr. Thierry Diagana
Head of the Novartis Institute for Tropical Diseases